Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC603 9-valent HPV vaccine in HIV-infected men with varying immune reconstitution
ChiCTR2600124229Phase 3Recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of human papillomavirus 9-valent vaccine, recombinant in human papillomavirus infection and human papillomavirus-related diseases (HPV) (3 arms), sponsored by Beijing Ditan Hospital. Primary endpoints: HPV type-specific antibody detection at 24 months, Safety endpoints and 3 more. Started May 2026; status: recruiting.
02
Drugs
human papillomavirus 9-valent vaccine, recombinant
03
Conditions
human papillomavirus infectionhuman papillomavirus-related diseases (HPV)
Beyond the preview
Go deeper on ChiCTR2600124229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124229.